Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK's NICE Says No To Two CML Drugs; Invites Cost-Sharing Schemes

Executive Summary

The UK cost-effectiveness watchdog NICE delivered a resounding "no" Feb. 9 to the use on the National Health Service of Bristol-Myers Squibb's Sprycel (dasatinib) and Novartis' Tasigna (nilotinib) in chronic myeloid leukemia patients who are intolerant to Glivec (imatinib, Gleevec in the U.S.)
Advertisement

Related Content

With Yervoy Approved in Europe, Bristol Activates Reimbursement Talks
NICE Rejects Leukemia Drugs On Eve Of Conference That Likely Will Debate Cancer Policies, NICE's Future
Tasigna Beats Sprycel To First-Line CML Punch
Tasigna Beats Sprycel To First-Line CML Punch
Goodbye Gleevec? Sprycel, Tasigna Vie For Front-Line CML Leadership
Reimbursement: The New Biopharma Investment Hurdle
Reimbursement: The New Biopharma Investment Hurdle
Cimzia UK Access Scheme Reinforces Marketing Message
Cimzia UK Access Scheme Reinforces Marketing Message
The Cost-Sharing Solution: The New NICE Ticket

Topics

Advertisement
UsernamePublicRestriction

Register

PS051939

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel